148 related articles for article (PubMed ID: 37999667)
21. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
22. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
23. Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives.
Wei GX; Du Y; Zhou YW; Li LJ; Qiu M
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):851-861. PubMed ID: 36107723
[TBL] [Abstract][Full Text] [Related]
24. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.
Blat D; Zigmond E; Alteber Z; Waks T; Eshhar Z
Mol Ther; 2014 May; 22(5):1018-28. PubMed ID: 24686242
[TBL] [Abstract][Full Text] [Related]
25. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
26. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in CAR-T cells therapy for colorectal cancer.
Qin X; Wu F; Chen C; Li Q
Front Immunol; 2022; 13():904137. PubMed ID: 36238297
[TBL] [Abstract][Full Text] [Related]
28. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
Ornella MSC; Badrinath N; Kim KA; Kim JH; Cho E; Hwang TH; Kim JJ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190310
[TBL] [Abstract][Full Text] [Related]
30. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.
Katz SC; Moody AE; Guha P; Hardaway JC; Prince E; LaPorte J; Stancu M; Slansky JE; Jordan KR; Schulick RD; Knight R; Saied A; Armenio V; Junghans RP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843493
[TBL] [Abstract][Full Text] [Related]
31. Is ascites CEA a risk factor for peritoneal carcinomatosis in colorectal cancer?: a long-term follow-up study.
Kim BC; Bae JH; Park SM; Won DY; Lee IK
Int J Colorectal Dis; 2020 Jan; 35(1):147-155. PubMed ID: 31802190
[TBL] [Abstract][Full Text] [Related]
32. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
[TBL] [Abstract][Full Text] [Related]
33. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
34. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
35. A chimeric antigen receptor-based cellular safeguard mechanism for selective
Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
[TBL] [Abstract][Full Text] [Related]
36. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
Sullivan KM; Jiang X; Guha P; Lausted C; Carter JA; Hsu C; Labadie KP; Kohli K; Kenerson HL; Daniel SK; Yan X; Meng C; Abbasi A; Chan M; Seo YD; Park JO; Crispe IN; Yeung RS; Kim TS; Gujral TS; Tian Q; Katz SC; Pillarisetty VG
Gut; 2023 Feb; 72(2):325-337. PubMed ID: 35705369
[TBL] [Abstract][Full Text] [Related]
37. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
38. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
39. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.
Schnalzger TE; de Groot MH; Zhang C; Mosa MH; Michels BE; Röder J; Darvishi T; Wels WS; Farin HF
EMBO J; 2019 Jun; 38(12):. PubMed ID: 31036555
[TBL] [Abstract][Full Text] [Related]
40. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
